Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer

BMC Cancer

Research Article

Rohini Sharma¹  Janet Graham²  Hani Gabra³  Sarah Blagden³ 

[1] Department of Experimental Medicine, Imperial College, London, UK;Department of Oncology, University of Glasgow, Glasgow, UK;Ovarian Cancer Action (HHMT) Research Centre, Imperial College, London, UK;

关键词: ovarian cancer;    resistance;    chemotherapy;    dose-dense;    carboplatin;    paclitaxel;    thrombocytopaenia;   

DOI  :  10.1186/1471-2407-11-289

 received in 2011-02-09, accepted in 2011-07-11,  发布年份 2011

来源: Springer

【 摘 要 】

BackgroundPlatinum agents have shown demonstrable activity in the treatment of patients with platinum resistant, recurrent ovarian cancer when delivered in a "dose-dense" fashion. However, the development of thrombocytopenia limits the weekly administration of carboplatin to no greater than AUC 2. Paclitaxel has a well-described platelet sparing effect however its use to explicitly provide thromboprotection in the context of dose dense carboplatin has not been explored.MethodsWe treated seven patients with platinum resistant ovarian cancer who had previously received paclitaxel or who had developed significant peripheral neuropathy precluding the use of further full dose weekly paclitaxel.ResultsWe were able to deliver carboplatin AUC 3 and paclitaxel 20 mg/m2 with no thrombocytopenia or worsening of neuropathic side-effects, and with good activity.ConclusionsWe conclude that this regimen may be feasible and active, and could be formally developed as a "platinum-focussed dose-dense scaffold" into which targeted therapies that reverse platinum resistance can be incorporated, and merits further evaluation.

【 授权许可】

CC BY   
© Sharma et al; licensee BioMed Central Ltd. 2011